Plowshare Therapies LLC — SEC Form D Filing
Plowshare Therapies LLC filed an SEC Form D on August 28, 2026, reporting $6.65M raised in Biotechnology.
Form D filing details
- Filing
- SEC Form D
- Filing date
- August 28, 2026
- Amount reported
- $6.65M
- Round stage
- Pre-Seed
- Industry
- Biotechnology
- Website
- https://www.plowsharetherapies.com/
What the company does
Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Children suffer from severe pediatric rare diseases, such as Maple Syrup Urine Disease (MSUD), which is a devastating metabolic disorder causing irreversible brain injury in newborns if untreated.
Solution
Plowshare Therapies is developing gene therapies to treat these conditions, starting with a gene therapy for MSUD that systemically delivers two corrected genes to restore the missing enzyme, designed as a single, lifetime treatment.
Why now
Advances in gene therapy technology and a deeper understanding of specific rare genetic disorders, combined with a commitment to serve underserved populations, enable the development of targeted, potentially curative treatments that were previously unavailable.
Verdict
Investors backed Plowshare Therapies on the promise of a single, curative gene therapy for a devastating pediatric rare disease, where existing treatments are merely palliative. This cleared because the market recognized the significant unmet medical need and the potential for a high-value therapeutic, not because the specific delivery mechanism or the full commercialization path was fully de-risked. They were implicitly betting on successful clinical translation and regulatory approval for an orphan drug, accepting the long development timeline. The limited upside stemmed from the narrow initial indication and the high cost of gene therapy development.
Source: SEC EDGAR Form D filing